RT Journal Article
SR Electronic
T1 Host-Microbe Multiomic Profiling Reveals Age-Dependent COVID-19 Immunopathology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.11.24301704
DO 10.1101/2024.02.11.24301704
A1 Phan, Hoang Van
A1 Tsitsiklis, Alexandra
A1 Maguire, Cole P.
A1 Haddad, Elias K.
A1 Becker, Patrice M.
A1 Kim-Schulze, Seunghee
A1 Lee, Brian
A1 Chen, Jing
A1 Hoch, Annmarie
A1 Pickering, Harry
A1 Zalm, Patrick Van
A1 Altman, Matthew C.
A1 Augustine, Alison D.
A1 Calfee, Carolyn S.
A1 Bosinger, Steve
A1 Cairns, Charles
A1 Eckalbar, Walter
A1 Guan, Leying
A1 Jayavelu, Naresh Doni
A1 Kleinstein, Steven H.
A1 Krammer, Florian
A1 Maecker, Holden T.
A1 Ozonoff, Al
A1 Peters, Bjoern
A1 Rouphael, Nadine
A1 IMPACC Network
A1 Montgomery, Ruth R.
A1 Reed, Elaine
A1 Schaenman, Joanna
A1 Steen, Hanno
A1 Levy, Ofer
A1 Diray-Arce, Joann
A1 Langelier, Charles R.
YR 2024
UL http://medrxiv.org/content/early/2024/02/13/2024.02.11.24301704.abstract
AB Age is a major risk factor for severe coronavirus disease-2019 (COVID-19), yet the mechanisms responsible for this relationship have remained incompletely understood. To address this, we evaluated the impact of aging on host and viral dynamics in a prospective, multicenter cohort of 1,031 patients hospitalized for COVID-19, ranging from 18 to 96 years of age. We performed blood transcriptomics and nasal metatranscriptomics, and measured peripheral blood immune cell populations, inflammatory protein expression, anti-SARS-CoV-2 antibodies, and anti-interferon (IFN) autoantibodies. We found that older age correlated with an increased SARS-CoV-2 viral load at the time of admission, and with delayed viral clearance over 28 days. This contributed to an age-dependent increase in type I IFN gene expression in both the respiratory tract and blood. We also observed age-dependent transcriptional increases in peripheral blood IFN-(, neutrophil degranulation, and Toll like receptor (TLR) signaling pathways, and decreases in T cell receptor (TCR) and B cell receptor signaling pathways. Over time, older adults exhibited a remarkably sustained induction of proinflammatory genes (e.g., CXCL6) and serum chemokines (e.g., CXCL9) compared to younger individuals, highlighting a striking age-dependent impairment in inflammation resolution. Augmented inflammatory signaling also involved the upper airway, where aging was associated with upregulation of TLR, IL17, type I IFN and IL1 pathways, and downregulation TCR and PD-1 signaling pathways. Metatranscriptomics revealed that the oldest adults exhibited disproportionate reactivation of herpes simplex virus and cytomegalovirus in the upper airway following hospitalization. Mass cytometry demonstrated that aging correlated with reduced naïve T and B cell populations, and increased monocytes and exhausted natural killer cells. Transcriptional and protein biomarkers of disease severity markedly differed with age, with the oldest adults exhibiting greater expression of TLR and inflammasome signaling genes, as well as proinflammatory proteins (e.g., IL6, CXCL8), in severe COVID-19 compared to mild/moderate disease. Anti-IFN autoantibody prevalence correlated with both age and disease severity. Taken together, this work profiles both host and microbe in the blood and airway to provide fresh insights into aging-related immune changes in a large cohort of vaccine-naïve COVID-19 patients. We observed age-dependent immune dysregulation at the transcriptional, protein and cellular levels, manifesting in an imbalance of inflammatory responses over the course of hospitalization, and suggesting potential new therapeutic targets.One sentence summary We observed age-dependent immune dysregulation at the transcriptional, protein and cellular levels, manifesting in an imbalance of inflammatory responses over the course of hospitalization, and suggesting potential new therapeutic targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the United States National Institutes of Health through the following grants: 5R01AI135803-03, 5U19AI118608-04, 5U19 AI128910-04, 5U19 AI089992, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, NIH-NIAID 3U19AI1289130 and U19AI128913-04S1 for EFR, R01 AI122220 for CC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NIAID staff conferred with the Department of Health and Human Services Office for Human Research Protections (OHRP) regarding potential applicability of the public health surveillance exception [45CFR46.102(l)(2)] to the IMPACC study protocol. OHRP concurred that the study satisfied criteria for the public health surveillance exception, and the IMPACC study team sent the study protocol, and participant information sheet for review, and assessment to institutional review boards (IRBs) at participating institutions. Twelve institutions elected to conduct the study as public health surveillance, while three sites with prior IRB-approved biobanking protocols elected to integrate and conduct IMPACC under their institutional protocols (University of Texas at Austin, IRB 2020-04-0117; University of California San Francisco, IRB 20-30497; Case Western reserve university, IRB STUDY20200573) with informed consent requirements. Participants enrolled under the public health surveillance exclusion were provided information sheets describing the study, samples to be collected, and plans for data de-identification, and use. Those that requested not to participate after reviewing the information sheet were not enrolled. In addition, participants did not receive compensation for study participation while inpatient, and subsequently were offered compensation during outpatient follow-ups. The International Committee of Medical Journal Editors (ICMJE) recommendations were followed for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available under restricted access to comply with NIH Public data sharing policy for IRB-exempted public surveillance studies. Access can be obtained via AccessClinicalData@NIAID (https://accessclinicaldata.niaid.nih.gov/study-viewer/clinical_trials). More information can also be found under https://docs.immport.org/home/impaccslides/. Data files were previously generated (2, 36, 63) and are available at ImmPort under accession number SDY1760 and dbGAP accession number phs002686.v1.p1 (clinical data version 2021-11-11-frozen). The healthy control aging transcriptomic dataset was obtained from a supplementary data file from Peters et al.(5). All analysis code has been deposited at https://bitbucket.org/kleinstein/impacc-public-code/src/master/aging_manuscript/. https://bitbucket.org/kleinstein/impacc-public-code/src/master/aging_manuscript/